source
- AAM warns that price pressures threaten sustainability of US generics and biosimilars marketThe Association for Accessible Medicines (AAM) issued its annual report warning that the economics of off‑patent drugs have deteriorated, putting the sustainability of the generic and biosimilar ma…
- Scholar Rock receives FDA approval for Isembyld, first muscle-targeted SMA therapyScholar Rock announced that its monoclonal antibody apitegromab, branded Isembyld, has been cleared by the FDA for treatment of spinal muscular atrophy (SMA). The approval follows a previous rejec…